Revitrane LED — BR Pharm Lab HA Filler with Lidocaine

Revitrane is BR Pharm Lab’s HA dermal filler — 24 mg/mL cross-linked hyaluronic acid + 0.3% lidocaine using patented LED cross-linking technology. Available in multiple variants for different facial zones. Engineered for mid-to-deep dermal placement targeting nasolabial folds, lip augmentation, and moderate facial contouring.

Revitrane LED HA Filler with Lidocaine is manufactured by BR Pharm Lab, a South Korea-based medical device and pharmaceutical company established in 2015. The product is part of the Revitrane dermal filler range, which is distributed across multiple international markets. Regulatory status: CE marked · KFDA registered · GMP certified.

Revitrane LED HA Filler with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using BR Pharm Lab’s LED Cross-Linking Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per BR Pharm Lab’s clinical data, Revitrane LED HA Filler with Lidocaine delivers Up to 12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Revitrane LED HA Filler with Lidocaine is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Revitrane LED HA Filler with Lidocaine regulatory status: CE marked · KFDA registered · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Revitrane LED HA Filler with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Revitrane LED HA Filler with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Revitrane LED HA Filler with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

LED is BR Pharm Lab’s proprietary HA cross-linking technology used across the Revitrane range. The process produces stable monophasic gel structure with sustained durability and natural-feeling integration into tissue. Revitrane is part of a broader Korean filler ecosystem of mid-density 24 mg/mL HA products — alongside Lexyal, Helene, and Sosum (lidocaine-free) — that share similar clinical profiles while differing in manufacturer-specific cross-linking nuances.